Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0022104 (
irritable bowel syndrome
)
8,033
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Carrageenan
(
CGN
), a family of marine polysaccharides isolated from seaweeds, has been at the heart of considerable debate in recent years. To date,
CGN
is generally recognized as safe based on a history of safe use, various acute toxicology studies and some recent chronic toxicology tests. This review offers readers an overview of evidence on
CGN
characteristics and digestive fate that highlight various gaps in our understanding. Specifically, three unresolved gaps are identified. Firstly, little information can be found on the current levels of public exposure to
CGN
. Secondly, the link between
CGN
physicochemical properties, its impact on digestive proteolysis, the colon microbiome and inflammation are yet to be fully resolved. Thirdly, scant scientific evidence exists on the differential digestive fate of
CGN
in the gut of liable and predisposed populations, such as elderly people or
IBD
patients. Altogether, revisiting the scientific evidence indicates that more research is needed to elucidate the possibility that continued exposure to increasing levels of
CGN
in the human diet may compromise human health and well-being.
...
PMID:Revisiting the carrageenan controversy: do we really understand the digestive fate and safety of carrageenan in our foods? 2946 13